Korean J Gastroenterol.  2024 Feb;83(2):78-80. 10.4166/kjg.2024.005.

Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma

• Chon HY

• KMID: 2553441
• DOI: http://doi.org/10.4166/kjg.2024.005

Reference

1. Sankar K, Gong J, Osipov A, et al. 2024; Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 30:1–15. DOI: 10.3350/cmh.2023.0125. PMID: 37482076. PMCID: PMC10776289.

2. Qin S, Chan SL, Gu S, et al. 2023; Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 402:1133–1146. DOI: 10.1016/S0140-6736(23)00961-3. PMID: 37499670.

3. Finn RS, Qin S, Ikeda M, et al. 2020; Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. DOI: 10.1056/NEJMoa1915745. PMID: 32402160.

4. Kelley RK, Rimassa L, Cheng AL, et al. 2022; Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 23:995–1008. DOI: 10.1016/S1470-2045(22)00326-6. PMID: 35798016.

5. Llovet JM, Kudo M, Merle P, et al. 2023; Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 24:1399–1410. DOI: 10.1016/S1470-2045(23)00469-2. PMID: 38039993.